Silvia Tonon

Dr. Silvia Tonon

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EMEleonora Martinis
Eleonora Martinis
STSilvia Tonon
Silvia Tonon
ACAlessandra Colamatteo
Alessandra Colamatteo
ACAntonio La Cava
Antonio La Cava
GMGiuseppe Matarese
Giuseppe Matarese
CPCarlo Pucillo
Carlo Pucillo

29 April 2019 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
STSilvia Tonon
Silvia Tonon
FMFrancesca Mion
Francesca Mion
JDJun Dong
Jun Dong
HCHyun-Dong Chang
Hyun-Dong Chang
Emiliano DallaEmiliano Dalla
Emiliano Dalla
CPCarlo Pucillo
Carlo Pucillo
Among the family of regulatory B cells, the subset able to produce interleukin‐10 (IL‐10) is the most studied, yet its biology is still a matter of investigation. The DNA methylation profiling of the il‐10 gene locus revealed a novel epigenetic signature characterizing murine B cells ready to respond through IL‐10 synthesis: a demethylated region located 4.5 kb from the transcription starting site (TSS), that we named early IL10 regulatory region (eIL10rr). This feature allows to distinguish B cells that are immediately prone and developmentally committed to IL‐10 production from those that require a persistent stimulation to exert an IL‐10‐mediated regulatory function. These late IL‐10 producers are instead characterized by a delayed IL10 regulatory region (dIL10rr), a partially demethylated DNA portion located 9 kb upstream from the TSS. A demethylated region was also found in human IL‐10‐producing B cells and, very interestingly, in some B‐cell malignancies, such as chronic lymphocytic leukemia and mantle cell lymphoma, characterized by an immunosuppressive microenvironment. Our findings define murine and human regulatory B cells as an epigenetically controlled functional state of mature B cell subsets and open a new perspective on IL‐10 regulation in B cells in homeostasis and disease.

17 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EMEleonora Martinis
Eleonora Martinis
CRCarolina Ricci
Carolina Ricci
CTCaterina Trevisan
Caterina Trevisan
GTGaia Tomadini
Gaia Tomadini
STSilvia Tonon
Silvia Tonon
Colorectal cancer represents 10% of all new cancer cases each year and accounts for almost 10% of all cancer deaths. According to the WHO, by 2040 there will be a 60% increase in colorectal cancer cases. These data highlight the need to explore new therapeutic strategies. Classical interventions include surgical resection, chemotherapy and radiotherapy, which are invasive strategies that have many side effects on the patients and greatly affect their quality of life. A great advance in the treatment of this cancer type, as well as of all the others, could be the development of a vaccination strategy preventing the onset, the progression or the relapse of the pathology. In this review, we summarize the main vaccination strategies that are being studied for the treatment of colorectal cancer (CRC) and finally explore the possibility of using B-cells for the development of a new type of vaccine.

20 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Luca Giovanni LocatelloLuca Giovanni Locatello
Luca Giovanni Locatello
STSilvia Tonon
Silvia Tonon
VMVincenzo Mele
Vincenzo Mele
SSSimone Santini
Simone Santini
CMCesare Miani
Cesare Miani
CPCarlo Pucillo
Carlo Pucillo
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory disorder whose complex immunopathogenesis has yet to be fully elucidated. Endotype-2 CRSwNP is the most common form of disease where eosinophils are the main drivers of inflammation. Traditional treatments for CRSwNP have centered around intranasal or systemic corticosteroids and endoscopic sinus surgery (ESS). However, recent advancements in targeted therapies have introduced novel biological agents that specifically target key inflammatory mediators such as IL-4, IL-5, and IL-13. These biologics offer promising options for patients with CRSwNP, particularly those who do not respond adequately to conventional treatments. Nonetheless, some patients do not satisfactorily respond to these drugs because of an insufficient blockade of the inflammatory process. The mast cell (MC) is another important (and somehow neglected) actor in the pathogenesis of CRSwNP, and the latest clinical and translational evidence in this field has been reviewed in the present paper.

9 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CRCarolina Ricci
Carolina Ricci
MPMatteo Pivetta
Matteo Pivetta
EMEleonora Martinis
Eleonora Martinis
VVViviana Valeri
Viviana Valeri
CCCarolina Colliva
Carolina Colliva
STSilvia Tonon
Silvia Tonon
Introduction: L-Tryptophan (Trp) metabolism is impaired across various chronic inflammatory pathologies, including Multiple Sclerosis (MS). Trp processing relies on three metabolic routes, namely Kynurenine, Serotonin and Indole pathways. The host microbiota significantly impacts Trp metabolism, primarily by being responsible for Indole metabolites production and secondarily by shaping both Kynurenine and Serotonin pathways. Pathological conditions and pharmaceutical treatments can elicit changes in microbial populations, leading to alterations in metabolites production and therefore determining rearrangements in host metabolism. Currently, no simultaneous exploration and comparison of all three Trp related metabolic routes has been performed in the context of MS patients before and after Ocrelizumab (OCR) treatment.Methods: By performing mass spectrometry on plasma samples collected from healthy controls and MS patients before and six months after OCR treatment we provided a comparative investigation of Trp metabolomics profile.Results and discussion: Our data points out to concurrent alterations of Trp-related pathways among both OCR treated and untreated MS patients. Furthermore, MS treated patients presented a pattern resembling health state for various metabolites across the pathways. The results reported in our research may contribute to unveiling new perspectives and understanding regarding MS pathogenetic mechanisms.

27 August 2026 in Translational Oncology
Verified
Journal Article
Open access
ECEleonora Capezzali
Eleonora Capezzali
Martina ArcieriMartina Arcieri
Martina Arcieri
STSilvia Tonon
Silvia Tonon
CRCarolina Ricci
Carolina Ricci
VVViviana Valeri
Viviana Valeri
BFBarbara Frossi
Barbara Frossi